IMUX Insider Trading
Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $100,395.00
Insider Selling (Last 12 Months): $0.00
Immunic Share Price & Price History
Current Price: $1.12
Price Change: ▲ Price Increase of +0.01 (0.90%)
As of 04/28/2025 05:00 PM ET
Immunic Insider Trading History
Immunic Institutional Trading History
Data available starting January 2016
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More on Immunic
Volume
358,326 shs
Average Volume
631,546 shs
Market Capitalization
$107.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.91
Who are the company insiders with the largest holdings of Immunic?